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Using biomarkers to model disease course effectively and make early prediction is a
challenging but critical path to improving diagnostic accuracy and designing
preventive trials for neurological disorders. Leveraging the domain knowledge that
certain neuroimaging biomarkers may reflect the disease pathology, we propose a
model inspired by the neural mass model from cognitive neuroscience to jointly
model nonlinear dynamic trajectories of the biomarkers. Under a nonlinear mixed‐
effects model framework, we introduce subject‐ and biomarker‐specific random
inflection points to characterize the critical time of underlying disease progression
as reflected in the biomarkers. A latent liability score is shared across biomarkers to
pool information. Our model allows assessing how the underlying disease
progression will affect the trajectories of the biomarkers, and, thus, is potentially
useful for individual disease management or preventive therapeutics. We propose
an EM algorithm for maximum likelihood estimation, where in the E step, a
normal approximation is used to facilitate numerical integration. We perform
extensive simulation studies and apply the method to analyze data from a large
multisite natural history study of Huntington’s Disease (HD). The results show that
some neuroimaging biomarker inflection points are early signs of the HD onset.
Finally, we develop an online tool to provide the individual prediction of the
biomarker trajectories given the medical history and baseline measurements.
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1 | INTRODUCTION
Neurodegenerative diseases are associated with degen-
eration and death of neurons that cause movement
disorder and mental dysfunction. Due to a lack of
objective biomarkers, disease diagnosis is almost exclu-
sively based on subjective clinical assessments toward the
late stage of the diseases. However, the pathological
process of these diseases usually starts years before the
clinical symptoms. Accurate determination of disease
stages is imperative for early diagnosis and intervention
to delay the disease onset. On the other hand, it has long
been recognized that certain biomarkers (physiological,
biochemical, and anatomical) manifest specific aspects of
the disease pathology (Petersen et al., 2010), so integrat-
ing these biomarkers into the diagnostic process is
potentially useful. In particular, understanding the
temporal trajectories of the biomarkers will enable
clinicians to more accurately anchor the disease diag-
nosis. Furthermore, the temporal ordering of pathological
changes indicated by biomarkers offers valuable
information to assist designing preventive trials.
Many studies of neurodegenerative diseases have
collected comprehensive clinical features and biomar-
kers. For example, the Alzheimer’s disease (AD) neuroi-
maging initiative includes a rich panel of novel cognitive
tests, biomarkers, and brain images collected every 6
months for as long as 6 years; two major natural history
studies of Huntington’s disease (HD), the Prospective
Huntington at Risk Observational Study (PHAROS), and
Neurobiological Predictors of HD Study (PREDICT‐HD),
collected neuroimaging measures including regional
brain volumes and clinical measures in cognitive,
functional, psychiatric, and motor domains during four
to seven visits within 10 years of follow‐up.
At the same time, conceptual models and computational
methods have been developed to evaluate the dynamics of
the biomarkers using the collected data. Jack et al. (2010)
proposed two principles in biomarker modeling for AD:
first, the biomarkers become abnormal in a temporally
ordered manner; second, the rate of alteration in each
biomarker follows a nonlinear course which is hypothe-
sized to be a sigmoid function of a conceptual, unobserved
cognitive impairment stage. In an updated model, Jack et al.
(2013) replaced the unknown cognitive impairment stage
by age. This model serves as a conceptual construct for
research studies using different biomarkers of various
neurodegenerative diseases related to one another under a
common framework. In particular, a sigmoidal shape, as
supported and validated by neuroimaging, biofluid, and
autopsy data (Caroli et al., 2010; Jedynak et al., 2012),
implies that the change of the disease‐related biomarkers
first accelerates and then decelerates, and that the rate of
the exacerbation reaches the peak at the inflection point of
the sigmoidal curve, which may vary between individuals
and biomarkers. Some biomarkers may never reach the
plateau before the disease onset (Sabuncu et al., 2011),
while for the other biomarkers, the peak times occur before
the disease onset so they may reflect critical stages of the
disease progression. The latter biomarkers are especially
useful for early diagnosis and prevention.
Nonparametric approaches (Paulsen et al., 2014b) and
the parametric sigmoidal model (Jedynak et al., 2012)
have been used to estimate the trajectories of the
biomarkers. These methods focus on modeling biomar-
ker‐level heterogeneity instead of subject‐level hetero-
geneity, while substantial between‐subject heterogeneity
is present and hypothesized to be attributed to differences
in cognitive reserve (CR). CR is defined as the brain
resilience to neuropathological damage and the ability to
maximize performance through differential recruitment
of brain networks (Scarmeas and Stern, 2004). Most of
the existing methods that ignore CR leave much of the
between‐subject variation unexplained and do not allow
for easy subject‐specific prediction. Later, Donohue et al.
(2014) used shape invariant modeling with time as the
horizontal axis and allowed subject‐specific scale and
location shift of time. However, this method does not
take into account the subject‐level covariates and ignores
subject‐level random effects. Furthermore, the existing
methods ignore the knowledge of similarity and shared
information among biomarkers from the same domain.
In this work, we propose a nonlinear mixed‐effects
model inspired by neural mass models in the theory of
cognitive neuroscience. We model each biomarker as a
sigmoidal curve that depends on subject‐specific covariates.
Moreover, we introduce subject‐specific and biomarker‐
specific random inflection points in the sigmoidal curves in
order to characterize the underlying critical disease progres-
sion points as measured by the biomarkers. The contribution
of this work is threefold. First, we postulate a biological
working model from cognitive neuroscience theories as a
generative model to account for CR. The resulting sigmoidal
shape for biomarkers is consistent with the population
model of Jack et al. (2010). Second, the model automatically
scales each biomarker into a common range on the vertical
axis, with age as the common horizontal axis, to allow for
between‐subject and between‐marker comparisons. The
model also jointly accommodates biomarkers from the
same domain by introducing shared subject‐specific inflec-
tion points with biomarker‐specific location and scale shifts.
Third, the generative model offers a computational tool to
circumvent the known computational difficulty for fitting
nonlinear mixed‐effects models. Existing procedures either
approximate the log‐likelihood function using numerical
approximation or adopt a linear mixed‐effects model as an
approximation. They become unstable when the true curves
are nonlinear and the model contains random components
in the horizontal direction. The convergence may also
heavily depend on the choice of initial values. In contrast,
our proposed method easily circumvents the computational
difficulty by drawing a connection with the neural mass
model and mean‐field approximation. More specifically, the
method treats each biomarker as the aggregated expression
of a large number of latent neuronal on‐off activities so the
EM algorithm can be used to treat the latent neuronal status
as missing. In the EM algorithm, a normal approximation is
used to facilitate numerical integration.
In Section 2, we propose a generative model and
provide model assumptions. We then describe the EM
algorithm for computing the maximum likelihood
estimates. In Section 3, we conduct extensive simulations
to demonstrate the finite‐sample performance. In Section
4, we apply the method to PREDICT‐HD (Paulsen et al.,
2014a) to estimate temporal ordering of regional brain
atrophies in HD and show how to perform individual
prediction of disease progression. We conclude with
some discussion in Section 5.
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2 | METHODS
2.1 | A potential biological model
Under mean‐field approximation, a generative mechanism
for neuronal dynamics assumes that activities of neural
ensembles (a group of neurons acting briefly as a closed
system) reflect the mean activities of latent states of
individual neurons. Furthermore, the abnormality of the
neural ensemble can be due to instantaneous neuronal loss,
neurofibrillary degeneration, or a lack of brain reserve or
CR. CR is a broad concept referring to susceptibility to
impairment, which varies with individual characteristics,
such as increased synaptic or neuronal capacity, greater
efficiency engaging brain networks, or the use of alternative
strategies. CR may mediate why some individuals better
tolerate neuronal insults and is associated with multiple
factors, such as genetic predisposition, education level, and
occupation (Stern, 2012).
To model the biomarkers using this generative
mechanism, we propose a model at the neural ensemble
level. Let i index subject, k index a biomarker, j index
observation time point, and s index neural ensemble.
First, to incorporate latent resilience to neurological
insult (related to CR), we define a latent binary variable,
Qiks, for ensemble s related to the kth biomarker of
patient i. We assume Qiks follow a Bernoulli distribution
with one representing that the sth ensemble does not
reach the threshold for damage. Define c P Q( = 1)ik iks≔
as the CR parameter representing CR capacity of patient
i, which may depend on the baseline covariates Zi (eg,
genetic variants, education level). The long‐term CR
capacity is assumed to be time‐invariant during a
relatively short observation period. It can also be viewed
as the lower bound of the percentage of active neural
ensembles manifested by a biomarker. Let X Z1= ( , ) ,i T iT T
we assume η Xc i n k Klogit( ) = , = 1, …, ; = 1, …, .ik k
T
i
Next, to model the neuronal dysfunction state at the
jth time point, we introduce binary random variable Bijks,
where B = 1ijks indicates that the ensemble is normal,
and B = 0ijks indicates abnormal. In the nonsusceptible
(reserved) state with Q = 1iks , there is no risk of
experiencing neuronal abnormality. Thus P
B Q( = 1 = 1) = 1ijks iks∣ for each time point j. In the
susceptible state with Q = 0iks , we assume that the
probability of maintaining a normal neuronal activity is
P B Q d
b t d
( = 1 = 0, )





where tijk is the age of subject i and bk is the biomarker‐
specific rate which is constrained to be nonpositive since
the probability of normal functioning decreases with
time. Furthermore, we assume that the inflection
point dik is associated with covariates, and dik of
different biomarkers for the same patient is correlated
through a shared latent variable Wi with biomarker‐
specific location and scale shifts. Specifically, we model
dik as
θ Zd μ χ W W N χ k
K
= + , ( , 1), 0,
= 1, …, .




This random inflection point describes the subject‐ and
biomarker‐specific age when the dynamic rate of a
biomarker reaches the maximum, and therefore, it is
the age when the change is most detectable. Note that the
inflection point can be used as the anchoring event to
describe that a patient has reached the halfway of the
pathophysiological pathway as manifested by the kth
biomarker.
The subject‐specific latent variableWi in (2) follows
a normal distribution with mean associated with
standardized Zi, and therefore, the mean of Wi is
anchored at the population‐average level of covariates.
It represents a latent liability score that measures the
relative severity of the disease in patients, where a
patient with a larger value indicates a milder condition
and a negative value indicates a condition more severe
than the population average. The model in (2) allows
correlation among biomarkers, by assuming that a
patient with a larger Wi will have delayed progression
of all biomarkers. The variance of Wi is set to 1 to
ensure identifiability. The parameter χk represents the
magnitude of manifestation ofWi in dik which allows a
different variance of the inflection points of each
biomarker, and μk is the inflection point of the kth
biomarker for an “average” patient with mean covari-
ate values.
We assume that Qiks of each ensemble is independent
and so is abnormality status Bijks. From the generative
model, the distribution of Bijks is a mixture of a point
mass and a Bernoulli random variable:
B Q Q H= + (1 − ) ,ijks iks iks ijks (3)
where Hijks is independent with Qiks, and
H d b t dBernoulli(1 {1 + exp[− ( − )]}).ijks ik k ijk ik∣ ∼ ∕
Suppose that each neural ensemble at a normal state
has a magnitude α Xa =ik kT i, the normal value of a
biomarker is then the average manifestation of all
ensembles: ( )a N B/ik i sN ijks=1i∑ , subject to degeneration of
normal aging and additional measurement errors.
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Here, the number of neural ensembles, Ni, is an auxiliary
variable which does not affect the estimation of mean
activity as long as it is large enough to ensure sufficient
approximation of means of Bernoulli random variables. The
observed biomarker k at time j for subject i is thus
( ) ( )
Y β t a
N
Q Q H v
v N σ N σ
= + [ + (1 − ) ] +





iks iks ijks ik









where vik is i.i.d. subject‐specific and biomarker‐specific
random effects, ϵijk is i.i.d. measurement error, and a
linear trend, β tk ijk, is introduced to represent the natural
degeneration associated with long‐term aging. Figure 2
illustrates the generative working model of different
markers under several layers of latent random variables.
From (1), (2), and (4), it is clear that the conditional
expectation of Yijk givenWi is
E Y W β t a c c
b t μ χ W
[ ] = + + 1 −
1 + exp{− ( − − )}
,ijk i k ijk ik ik
ik








in which the second part of the right‐hand side coincides
with the sigmoidal assumption of the model in Jack et al.
(2010), with an upper bound of aik when t −→ ∞ and a
lower bound of a cik ik when t +→ ∞. Therefore, a
biomarker showing no pathological abnormality is
expected to change linearly since a β t+ik k corresponds
to long‐term aging, while the mean of a biomarker
with abnormality will start from the asymptote line
a β t+ik k , decline as a sigmoid curve, and eventually
reach another asymptote line β t a c+k ik ik. The additional
declination is a c(1 − )ik ik . Under some weak assump-
tions, all the parameters in the proposed model are
identifiable (proof of identifiability is in Supporting
Information Section A).
2.2 | Estimation methods
For notational convenience, we denote Qik≔⋅
N Q R N Q H, (1 − )i s
N







i i∑ ≔ ∑⋅ , which re-
present the average ensemble performance and denote
Y j n, = 1, …,ijk ik as vector Y R j n, , = 1, …,ik ijk ik⋅ as
vector Rik⋅. Note that RQ ,ik ik⋅ ⋅, and Wi are treated as
missing data. We assume independence between
FIGURE 1 The four neuroimaging biomarkers with data of 100 patients exhibited (colored longitudinal trajectories). The black line is
the estimated mean level XE Y W0( = , = 0)∣ with linear slope and sigmoid curve, and the bootstrap confidence band is overlaid in gray
[This figure appears in color in the electronic version of this article, and any mention of color refers to that version]
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subjects, and the conditional independence of markers
from the same subject given Wi . Thereby, the complete
log‐likelihood function from models (1) to (4) for
RQ v W i n k KY( , , , , ), = 1, …, , = 1, …,ik ik ik i ik⋅ ⋅ is
( )
( )
( ) ( )
Y R α X
R η X
θ Z
l l Q v β σ
l Q W μ χ b
l v σ l W
= , , , , , ;
+ , , , , , ;






































The observed likelihood function is thus the integration
of lexp{ }n over W and v’s and the summation over
discrete variables Q’s and H ’s. To obtain the maximum
likelihood estimates, we apply EM algorithm.
2.3 | EM algorithm
The E step computes the conditional expectation of the
log‐likelihood of the complete data with respect to
the distribution of the missing data RQ v W( , , , )ik ik ik i⋅ ⋅ ,
given the observed data Yik, covariates X ,i
i n k K= 1, …, , = 1, …, , and the current estimated para-
meter values. The M step separately maximizes the four
components of the complete log‐likelihood replacing the
FIGURE 2 Didactic graph of data generative mechanism. The three trajectories at the bottom correspond to (5) with
α b c μ= 100, 80, 120, = −0.2, −0.3, −0.6, = 0.4, 0.3, 0.6, = 40, 50, 60k k k k0 [This figure appears in color in the electronic version of this
article, and any mention of color refers to that version]
( )
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( ) ( )
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missing data terms by their conditional expectations to
obtain the updates for four groups of parameters
α ηβ σ σ μ χ b( , , ), , ( , , , )k k k vk k k k kϵ2 2 , and θ. The updates of
α ηβ σ σ( , , ), ,k k k vk kϵ2 2 , and θ have analytic solutions. For
b μ χ( , , )k k k which has no analytic solution, we apply one‐
step Newton‐Raphson method to approximate the root of
the score function. We only show the M step for updating
αβ( , )k k and b μ χ( , , )k k k . The details of solving the system
of score functions are skipped, where each optimization is
much easier compared to the original model.
M step: We denote E [ ] ⋅ as the conditional expectation
given the observed data and current estimated para-
meters. In the M step, we solve the following equations to
update the parameter estimates in a sequential way. For
αk and β k K, = 1, …,k , we solve
α
β
E Q R E Q R t
E Q R t t
E Q R Y v





[( + ) ] [( + )]
[( + )]
×










ik ijk i ik ijk ijk
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⋅ ⋅ ⋅ ⋅
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⋅ ⋅
For b μ,k k and χ k K, = 1, …,k , let γ γ γ γ= ( , , )k k k T1 1 1 ,
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by one‐step Newton‐Raphson, which requires the second
derivative of the above equations with respect to
γ γ γ( , , )k k k1 2 3 :
J
E
Q γ t γ γ W t W t W
γ t γ γ W
= −
(1 − )exp{ + + }( , 1, ) ( , 1, )






ik k ijk k k i ijk i
T
ijk i















We denote three components of the left side of Equation
(6) as γ γ γL L L( ), ( ), ( )1 2 3 , and then, we update γ by
( ) ( ) ( )γ γ γ γ γJ L L L= − , , T(new) (old) −1 1 (old) 2 (old) 3 (old)⎡⎣ ⎤⎦
and update b μ,k k, and χk using b γ μ γ γ= , = −k k k k k1 2 1∕ ,
and χ γ γ= − .k k k3 1∕
The conditional expectations in the above equations
need to be evaluated in the E step. However, when Ni is
large, it is computationally challenging to enumerate all
possible combinations of Qiks and Rijks. We will elaborate
a method to avoid the summation over all possible Qiks’s
and Rijks’s in the next section.
E step: The equations in the M step show that all the
conditional expectations take the form of
E g Q R v g W[ ( , , ) ( )],ik ijk ik i1 2 ⋅ ⋅ where both g1 and g2 are some
integrable functions. In particular, g1 is some linear or
quadratic function ofQik⋅ and Rijk⋅ or the product between
Q R,ik ijk⋅ ⋅, and vi with order less than 2. To evaluate this
conditional expectation given observed data, we first
calculate the conditional expectation given observed data
plusWi and then take expectation withWi :
E g Q R v g W
E E g Q R v W g W
[ ( , , ) ( )]
= [ [ ( , , ) ] ( )].
ik ijk ik i







The conditional expectation of E g Q R v W[ ( , , ) ]ik ijk ik i1 ∣⋅ ⋅
requires enumerating all possible combinations of Qiks
and Rijks’s, which is computationally demanding. Obser-
ving that Qiks and Rijks appear in the likelihood function
in the form ofQik⋅ and Rijk⋅ and by assuming a large Ni, we
can approximate the averages, Qik⋅ and Rijk⋅, using
multivariate normal distribution by the central limit
theorem. That is, we approximate
( ) AQ R R W B, , …, MVN( , ),ik i k in k T i ik ik1 ik ∼⋅ ⋅ ⋅ (8)
where Aik and Σik are derived from the distribution of
Qiks and Rijks based on (1), (2), and (3). Denote





exp b t μ χ W[− ( − − )]))k ijk k k i , and then A =ik
[ ]c c p c p, (1 − ) , …, (1 − )ik ik i k ik in k T1 ik . The covariance Bik
has corresponding terms Q c c NVar( ) = (1 − ) , Varik ik ik i∕⋅
R p c p c p N R( ) = (1 − )(1 − + ) , cov( ,ijk ijk ik ijk ik ijk i ijk⎤⎦∕⋅ ⋅
R c c p p N) = (1 − )ij k ik ik ijk ij k i′ ′ ∕⋅ , and R Qcov( , ) =ijk ik⋅ ⋅
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, , …, −
, , …, − .












∣ ∣ ⋅ ⋅ ⋅
⋅ ⋅ ⋅
Note that the only term that contains Wi is pijk. It is
convenient to combine this vector with vik and form the
vector [ ]U Q R R v= , , …, ,ik ik i k in k ik T1 ik⋅ ⋅ ⋅ as having a multi-
variate normal distribution givenWi :
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i
and E a a I σ I1 1 , Σik ik ik n ik nϵ2ik k ik⎣
Let Cik = 
⎡
k − βkY tik, where⎤ 
tik is the vector of visit ages,
⎦≔ ≔ , in which 1 is a
column vector of all 1’s, Inik is n n×ik ik identity matrix,
and α Xa =ik iT k. The likelihood function lik(1) is then
represented as − (1/2) log ∣Σik −∣ (1/2) C UE( − )ik ik ik T
C UEΣ ( − )ik ik ik ik−1 . Since the density function of the data
and the latent variable is conjugate, it is convenient to
directly derive the posterior distribution of Uik given Yik
andWi , which is still a multivariate normal distribution:
( )
U C C AW D E B D
D E E B
, MVN( {Σ + ˜ ˜ }, ),
Σ + ˜ .
ik ik i ik ik ik
T








The conditional expectation E g Q R v W[ ( , , ) ]ik ijk ik i1 ∣⋅ ⋅ can
be easily derived from the posterior mean and posterior
covariance of Uik. After turning each expectation into a
function of Wi , we use Gauss‐Hermite quadratures to
evaluate the integration with respect to Wi . The
numerical integration requires only one‐dimensional
integral of Wi , which makes the model computationally
easy. The details of computing the conditional expecta-
tions and numerical integration is in Supporting In-
formation Section B.
The initials of parameters αβ( , )k k for each biomarker
in the EM algorithm are obtained from a linear mixed‐
effects model, which assumes c b= 1, = 0ik k and thus the
sigmoidal part does not exist. The convergence criterion
is set as the change of log‐likelihood stays within 0.05% of
the current step estimated log‐likelihood. The E step and
M step are iterated until convergence.
3 | SIMULATION STUDIES
We simulated two biomarkers based on the data
generative mechanism with the number of patients
n = 100, 200. We also assessed sensitivity to the choice
of Ni by using constant 100 or 10,000. The simulations are
based on the binomial model. The age of visits and the
covariate (cytosine‐adenine‐guanine [CAG] repeat length
at the huntingtin gene) were fixed at the observed values
of a subset of patients from PREDICT‐HD study. CAG
covariate was standardized. For both scenarios, we
generated 1,000 datasets using fixed parameters. For
each dataset, we estimated the 95% bootstrap confidence
intervals (CIs) based on 2.5 and 97.5 percentiles from
estimates using 1,000 bootstrap samples, and the cover-
age probability (CP) is defined as the proportion of times
the CI covers the true values of parameters.
The true value of parameters, mean and median bias,
standard error, and the CP are listed in Table 1. The
result shows that the algorithm is stable and the
estimation is robust under different Ni (changes within
2% for 95% of the parameters). The parameters of interest
in our application are b μ χ( , , )k k k , which determine the
rate of change of each biomarker and the temporal order
among different biomarkers. For the average inflection
point μk, the largest mean bias is− 0.16 year, and the SD
decreases from 0.45 to 0.34 year for the first biomarker
and from 0.57 to 0.39 year when the sample size increases
from 100 to 200 patients. The estimation of bk is also
precise with mean bias less than 1% of the absolute value
of the true value. The adequate estimation performance
of b μ χ( , , )k k k demonstrates that the strategy of translat-
ing the optimization to linear optimization through a
latent working model is successful in terms of estimation.
The covariate coefficient α η k, , = 1, 2k k1 1 , and θ are also
well estimated with small mean and median bias and
relatively small standard error. With initial values and
the convergence criterion aforementioned in E step, the
algorithm converges after about 20 to 40 iterations.
4 | APPLICATION
HD is an autosomal dominant neurodegenerative
disorder caused by the expansion of trinucleotide CAG
repeats in the huntingtin gene. PREDICT‐HD is a
long‐term, prospective study of HD that collected
baseline features of patients including demographics,
genetic features, longitudinal data of biomarkers, and
clinical measures from different domains in patients at
various stages of the disease. The main interest is
in estimating the effect of CAG repeat length on
the inflection points and CR parameters of several
neuroimaging measures, and assessing their temporal
order of degeneration.
In PREDICT, participants were prospectively followed
up to 10 years and clinical assessments and biomarkers
were continued to be collected after HD diagnosis. The
data consist of 217 patients with HD mutation (CAG
36≥ ), each with at least four longitudinal observations of
four key neuroimaging biomarkers: caudate, putamen,
hippocampus, and thalamus. The dropout rate was less
than 5% per year (Paulsen et al., 2014a). The dropouts
were mostly due to administrative reasons, and thereby
are assumed to be noninformative.
The four regions of interest are critical areas related to
pathological progression and clinical symptoms of HD:
caudate and putamen (in the striatum) are the main
components of the base of brain that control muscle‐
driven movements of the body, or “motor movement”;
emerging evidence from animal models of HD suggests
that some of the early cognitive deficits may have a
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TABLE 1 Simulation result of the two‐biomarker model
Marker 1 Marker 2
N, n Par True MeanB MedianB SD SE CP% True MeanB MedianB SD SE CP%
100, 100 βk –0.1 –0.006 –0.006 0.008 0.009 91.9 –0.2 –0.002 –0.001 0.017 0.016 93.8
αk0 66 0.114 0.171 0.365 0.362 92.5 56 0.056 0.061 0.490 0.484 94.6
αk1 –3 0.021 0.018 0.172 0.170 93.2 –4 0.004 –0.016 0.117 0.133 96.0
ηk0 0.3 0.016 0.015 0.064 0.061 94.5 0.2 0.001 0.008 0.084 0.085 94.9
ηk1 1 0.007 0.007 0.066 0.065 95.2 2 0.024 0.022 0.090 0.104 96.1
θ –4 0.139 0.072 0.821 0.992 95.9 –4 0.139 0.072 0.821 0.992 95.9
bk –0.2 –0.001 –0.001 0.010 0.009 94.1 –0.3 0.002 0.002 0.016 0.020 95.7
μk 41 –0.046 –0.045 0.448 0.440 95.1 42 –0.161 –0.110 0.571 0.572 96.2
χk 1 0.021 0.055 0.210 0.188 93.1 2 0.064 0.070 0.331 0.339 92.8
σvk 0.63 0.053 0.034 0.134 0.138 94.0 0.66 0.025 0.014 0.127 0.135 95.2
σ kϵ 0.58 0.021 0.025 0.099 0.097 92.1 1.15 –0.003 –0.015 0.061 0.062 94.9
ck 0.57 0.008 0.005 0.015 0.014 94.9 0.55 0.000 0.000 0.020 0.020 93.9
100, 200 βk –0.1 –0.005 –0.006 0.007 0.008 92.8 –0.2 0.001 0.001 0.012 0.013 93.6
αk0 66 0.119 0.115 0.235 0.228 94.6 56 –0.012 –0.034 0.348 0.318 93.7
αk1 –3 0.028 0.035 0.117 0.115 95.0 –4 0.003 –0.012 0.084 0.090 95.3
ηk0 0.3 0.032 0.030 0.052 0.043 93.1 0.2 0.000 0.002 0.051 0.057 96.2
ηk1 1 0.001 0.004 0.042 0.042 92.9 2 0.011 0.008 0.056 0.060 93.3
θ –4 0.043 –0.028 0.496 0.505 96.6 –4 0.043 –0.026 0.496 0.505 96.6
bk –0.2 –0.002 –0.003 0.005 0.005 92.9 –0.3 0.000 –0.001 0.011 0.012 97.5
μk 41 –0.067 –0.079 0.340 0.318 94.5 42 –0.081 –0.023 0.386 0.423 95.2
χk 1 0.012 0.007 0.112 0.113 92.9 2 0.004 –0.028 0.220 0.217 93.5
σvk 0.63 0.023 0.025 0.081 0.088 96.5 0.66 –0.007 –0.016 0.072 0.089 95.2
σ kϵ 0.58 0.029 0.032 0.069 0.067 92.2 1.15 0.001 0.003 0.043 0.040 94.9
ck 0.57 0.012 0.007 0.011 0.009 92.4 0.55 0.000 0.001 0.011 0.012 95.5
10,000, 200 βk –0.1 –0.006 –0.006 0.007 0.008 92.0 –0.2 0.001 0.001 0.013 0.011 93.4
αk0 66 0.120 0.113 0.232 0.225 94.3 56 –0.015 –0.032 0.342 0.312 94.6
αk1 –3 0.028 0.035 0.115 0.115 93.6 –4 0.003 –0.010 0.079 0.093 95.2
ηk0 0.3 0.032 0.031 0.050 0.042 93.1 0.2 0.000 0.002 0.052 0.057 95.5
ηk1 1 0.001 0.004 0.040 0.038 94.5 2 0.011 0.008 0.056 0.060 94.3
θ –4 0.042 –0.027 0.495 0.506 96.2 –4 0.042 –0.027 0.495 0.506 96.2
bk –0.2 –0.002 –0.003 0.006 0.006 93.8 –0.3 0.000 –0.001 0.011 0.012 96.3
μk 41 –0.069 –0.080 0.336 0.314 95.0 42 –0.081 –0.023 0.387 0.420 97.5
χk 1 0.012 0.007 0.112 0.114 92.9 2 0.004 –0.029 0.223 0.220 94.5
σvk 0.63 0.025 0.027 0.081 0.087 95.4 0.66 –0.007 –0.014 0.072 0.087 97.2
σ kϵ 0.58 0.029 0.032 0.069 0.068 93.0 1.15 0.001 0.003 0.043 0.040 94.9
ck 0.57 0.012 0.007 0.011 0.009 94.1 0.55 0.000 0.001 0.012 0.014 95.2
Note: In the table, N represents the number of neuron ensembles simulated, and n is the number of patients simulated. We listed the results for the three
different settings of N, n. The true parameters are listed in the column “True.” The column “MeanB” and “MedianB” is the mean and median bias of estimate
from the truth. For the kth biomarker, βk is the coefficient of linear trend of time; αk is the coefficient vector of covariates in estimating the scale parameter ak;
ηk is the coefficient vector of covariates in estimating clogit( )k , where ck is the CR parameter; μk is the mean inflection point of the sigmoid curve for an average
subject with mean covariates; χk is the scale parameter for the latent variableWi ; σvk and σ kϵ are the SD of the random effect and measurement error,
respectively; and θ is the shared coefficient vector of covariates in estimatingWi across biomarkers.
Abbreviation: CP, coverage probability.
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hippocampal basis (Duyao et al., 1993); thalamic 
degeneration contributes to the impairment of executive 
function in early HD (Kassubek et al., 2005). Neuronal 
loss in striatum is mainly related to motor function and 
neuronal loss in thalamus is more associated with 
cognitive impairment and poor performance in executive 
tests. However, there is little knowledge about when, 
during the course of HD, thalamic degeneration sets in 
compared with caudate and putamen. Thus, it is 
important to determine the progression of atrophy of 
each area to understand the occurrence of motor 
dysfunction and cognitive dysfunction.
We applied the model to the four biomarkers using 
three covariates: CAG repeat length, gender, and 
diagnostic confidence level (DCL) of the Unified HD 
Rating Scale (UHDRS) (ie, a rating of 0 to 4 with 
1 = normal, 4 = motor abnormalities that are unequivocal 
signs of HD (> 99% confidence)). All three covariates
were measured at baseline and standardized. Among 
them there is no significant correlation. We conducted 
the estimation separately with three choices of 
Ni: 100, 10, 000, and a subject‐specific number propor-
tional to intracranial volume with a range 37 to 62. The 
result shows that the algorithm is stable and the 
estimated parameters are robust under different Ni. The
CIs of the biomarker trajectories were calculated based 
on 2.5% and 97.5% percentiles of the estimates from 
bootstrap samples.
Figure 1 shows the estimated mean trajectory,
ZE Y W0( = , = 0)∣ , the 95% CI, and observed data from
100 patients. The CIs for hippocampus and thalamus are
relatively wider. The results in Table 2 show that the
linear slope βk is significant only for putamen and
hippocampus. For the scale parameter aik, male has a
significant lower value for all biomarkers, whereas CAG
repeats length is only significant for hippocampus. CR
parameter cik, as a measurement for the worst level a
biomarker deteriorates to, can be evaluated through
Xc η= logit ( )ik k
T
i
−1 . We report the average CR estimate
when the covariates are fixed at the sample means
(denoted as ck in Tables 1 and 2). For an average patient,
the CR parameter is around 0.30 (SD = 0.009) for
putamen, 0.19 (SD = 0.007) for caudate, 0.47 (SD = 0.007)
for hippocampus, and 0.62 (SD= 0.006) for thalamus. It
can be viewed as the percentage of normal units at the
end‐stage of HD. The higher CR parameter for hippo-
campus and thalamus suggests that the impairment is
less severe compared with caudate and putamen. This is
consistent with previously reported findings of HD
patients showing that adjacent nonstriatal regions, such
as the thalamus, remain mostly intact (Vonsattel et al.,
1985), and atrophy of the hippocampus is around 35% at
the end‐stage of HD (Spargo et al., 1993). The effect of
CAG on the CR parameter is significant only for caudate
and putamen: with one SD increase of CAG, the log‐odds
ratio for CR resilience (ie, Q = 1ik ) is − 0.71 for putamen
and − 0.73 for caudate. This indicates that CR decreases
as CAG repeats increases. A higher DCL reduces CR for
caudate only. Gender shows no significant effect on CR
(Figure 2).
The results show a significant effect of CAG repeat
length on the latent liability score θ ZWE( ) =i T i, which is
the shared component in the inflection points dik across
the four biomarkers. By the relation d χ W μ= +ik k i k, the
effect of CAG repeats on inflection point dik is further
amplified for caudate and putamen, with χ = 7.2 and 8.8,
compared with χ = 5.6 and 5.9 for hippocampus and
thalamus. On average, in patients with two more CAG
repeats (1 SD of CAG), the inflection point shifts
backward by 4.97 years for putamen and 6.07 years for
caudate. The relatively large value of χ implies a greater
biological variability of the distribution of the inflection
points for putamen and caudate compared with hippo-
campus, and thalamus. Figure 3 shows the probability of
the normal status, P B( = 1)ijks , for a patient with CAG
= 40, 42, 44, 46 and other covariates at the mean level. As
CAG repeats length increases, the curves move toward an
earlier inflection point age and decrease to a lower level.
Caudate and putamen are further separated from
hippocampus and thalamus. Gender and DCL show no
significant effect onWi .
The age at the inflection point for a patient with score
W = 0i is 38.0, 42.4, 45.0, and 51.8 years for caudate,
putamen, hippocampus, and thalamus. Aylward et al.
(2004) found that the time when caudate area atrophy
becomes significantly different from that of control
patients was about 2 years earlier than that of putamen.
Our estimation of the order of the progression of
putamen and caudate is consistent with Aylward et al.
(2004), while our estimation of the time gap is larger.
This is because we used the inflection point of
each sigmoid curve as an anchoring event rather than
the gap at the early stage when each curve starts to
decline. The average inflection point of the thalamus is
about 10 years later than that of caudate and putamen,
which validates the observation that neuronal loss within
thalamus may occur in the end‐stage HD patients at
autopsy (Vonsattel et al., 1985). Another way to evaluate
the inflection point age is to integrate dik under the
conditional distribution of Wi given the observed bio-
marker data. The details are in Supporting Information
Section C.
We compared the prediction performance of our method
with other methods including linear mixed effects (LME)
model, nonlinear mixed effects (NLME) model, and general-
ized additive model (GAM). We used cross‐validation to
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TABLE 2 Model results of the four neuroimaging biomarkers from PREDICT‐HD data
N Par Cov Putamen SD Caudate SD Hippo SD Thalamus SD
100 βk –0.004 0.001 –0.012 0.007 –0.007 0.002 –0.004 0.004
αk0 71.801 0.095 72.097 0.610 29.945 0.094 114.355 0.231
αk1 CAG 0.066 0.044 0.490 0.246 –0.295 0.022 –0.058 0.054
αk2 Gender –0.604 0.023 –0.916 0.189 –0.280 0.010 –0.492 0.020
αk3 DCL –0.356 0.032 –1.531 0.237 –0.294 0.010 –0.015 0.027
ηk0 –0.860 0.042 –1.482 0.049 –0.106 0.029 0.489 0.026
ηk1 CAG –0.710 0.077 –0.728 0.092 –0.022 0.042 0.012 0.043
ηk2 Gender –0.059 0.059 –0.038 0.075 –0.044 0.043 –0.042 0.033
ηk3 DCL –0.117 0.063 –0.211 0.083 –0.001 0.045 –0.050 0.034
θ1 CAG –0.689 0.159 –0.689 0.159 –0.689 0.159 –0.689 0.159
θ2 Gender –0.058 0.115 –0.058 0.115 –0.058 0.115 –0.058 0.115
θ3 DCL –0.114 0.128 –0.114 0.128 –0.114 0.128 –0.114 0.128
bk –0.073 0.003 –0.053 0.003 –0.063 0.003 –0.057 0.003
μk 42.447 0.362 37.962 0.563 45.009 0.598 51.818 0.776
χk 7.225 0.559 8.794 0.643 5.650 1.245 5.906 1.539
σvk 2.332 0.412 2.814 0.549 2.004 0.148 4.572 0.325
σ kϵ 1.971 0.106 3.143 0.141 0.919 0.055 2.856 0.180
ck 0.299 0.009 0.185 0.007 0.473 0.007 0.620 0.006
10,000 βk –0.004 0.001 –0.011 0.007 –0.007 0.002 –0.004 0.004
αk0 71.779 0.098 72.075 0.599 30.019 0.100 114.417 0.241
αk1 CAG 0.062 0.048 0.488 0.221 –0.289 0.025 –0.055 0.050
αk2 Gender –0.611 0.029 –0.922 0.178 –0.278 0.008 –0.497 0.034
αk3 DCL –0.349 0.031 –1.539 0.190 –0.303 0.010 –0.015 0.026
ηk0 –0.852 0.041 –1.485 0.051 –0.107 0.028 0.486 0.022
ηk1 CAG –0.714 0.079 –0.723 0.087 –0.022 0.039 0.013 0.041
ηk2 Gender –0.057 0.058 –0.038 0.081 –0.039 0.046 –0.043 0.031
ηk3 DCL –0.113 0.061 –0.212 0.084 –0.001 0.044 –0.042 0.030
θ1 CAG –0.683 0.132 –0.683 0.132 –0.683 0.132 –0.683 0.132
θ2 Gender –0.060 0.120 –0.060 0.120 –0.060 0.120 –0.060 0.120
θ3 DCL –0.114 0.126 –0.114 0.126 –0.114 0.126 –0.114 0.126
bk –0.072 0.003 –0.053 0.004 –0.064 0.002 –0.057 0.003
μk 42.451 0.384 37.991 0.550 45.045 0.702 51.800 0.686
χk 7.240 0.566 8.751 0.712 5.611 1.298 5.917 1.602
σvk 2.354 0.672 2.840 0.609 1.989 0.133 4.591 0.341
σ kϵ 1.973 0.099 3.148 0.145 0.920 0.052 2.858 0.183
ck 0.298 0.008 0.185 0.006 0.473 0.006 0.619 0.006
∝ to ICV βk –0.004 0.001 –0.012 0.006 –0.007 0.003 –0.006 0.006
αk0 71.781 0.111 72.041 0.559 30.001 0.090 114.015 0.253
αk1 CAG 0.009 0.019 0.421 0.217 –0.219 0.024 –0.049 0.060
αk2 Gender –0.598 0.031 –0.931 0.171 –0.281 0.015 –0.450 0.026
αk3 DCL –0.351 0.029 –1.500 0.258 –0.266 0.021 –0.014 0.020
ηk0 –0.848 0.050 –1.495 0.0694 –0.105 0.025 0.491 0.030
ηk1 CAG –0.612 0.067 –0.711 0.112 –0.021 0.042 0.015 0.049
(Continues)
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TABLE 2 (Continued)
N Par Cov Putamen SD Caudate SD Hippo SD Thalamus SD
ηk2 Gender –0.066 0.063 –0.013 0.066 –0.051 0.039 –0.049 0.032
ηk3 DCL –0.129 0.060 –0.220 0.090 –0.004 0.050 –0.044 0.029
θ1 CAG –0.683 0.161 –0.683 0.161 –0.683 0.161 –0.683 0.161
θ2 Gender –0.052 0.118 –0.052 0.118 –0.052 0.118 –0.052 0.118
θ3 DCL –0.115 0.130 –0.115 0.130 –0.115 0.130 –0.115 0.130
bk –0.072 0.004 –0.055 0.003 –0.063 0.004 –0.057 0.005
μk 42.412 0.400 38.007 0.581 45.001 0.555 51.791 0.703
χk 7.242 0.602 8.780 0.659 5.619 1.222 5.911 1.524
σvk 2.311 0.432 2.786 0.532 2.022 0.147 4.611 0.320
σ kϵ 1.970 0.102 3.142 0.139 0.917 0.050 2.854 0.182
ck 0.299 0.009 0.183 0.007 0.474 0.007 0.620 0.007
Note: In the table, N is the number of neuron ensembles assumed. For the kth biomarker, βk is the coefficient of linear trend of time; αk is the coefficient vector
of covariates in estimating the scale parameter ak; ηk is the coefficient vector of covariates in estimating clogit( )k , where ck is the CR parameter; μk is the mean
inflection point of the sigmoid curve for an average subject with mean covariates, χk is the scale parameter for the latent variableWi ; σvk and σ kϵ are the SD of
the random effect and measurement error, respectively; and θ is the shared coefficient vector of covariates in estimatingWi across biomarkers.
Abbreviations: CAG, cytosine‐adenine‐guanine; DCL, diagnostic confidence level.
FIGURE 3 Estimated P B( = 1 CAG = 40, 42, 44, 46)ijks ∣ for subpopulations in PREDICT‐HD data with CAG= 40 (upper left), CAG= 42
(upper right), CAG= 44 (bottom left), and CAG= 46 (bottom right) with other covariates fixed at the sample mean. The vertical dashed line is
inflection point and the horizontal dashed line in lower limit of sigmoid curve. This can be used as standardized biomarker values. The lower
bound of each biomarker at the end‐stage follows an order: Thalamus >Hippocampus > Putamen>Caudate. CAG, cytosine‐adenine‐guanine
[This figure appears in color in the electronic version of this article, and any mention of color refers to that version]
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implement methods on 90% (ie, 195 subjects) of data and
performed prediction on 10% of the data (ie, 22 testing
subjects). The process was repeated 100 times. Bio-
markers were fitted separately. The LME model contains
the same covariates as our model: β XY β t= + +k iijk k ijk
T
0
v + ϵik ijk, and the same for GAM: Y β g t= + ( ) +ijk k k ijk0
g X g X g X( ) + ( ) + ( )k i k i k i1 1 2 2 3 3 , in which g function is from
cubic spline space. The NLME: Y β t a c= + ( +ijk k ijk ik ik
c b t d v(1 − ) (1 + exp(− ( − ))) + + ϵik k ik ik ijk∕ with subject‐
level random effects in dik incurred convergence issues
when applied to the HD data, and thereby, the results are not
shown. Table 3 shows that our method, which is the only
one that accounts for the correlation between the biomar-
kers, outperforms the other investigated methods by more
than 10% decrease of the prediction error. In addition, our
method can be used to predict dynamic changes of
biomarkers and inflection points for a new patient based
on his or her baseline measures. An online application is
designed. We show details in Supporting Information
Section C.
In summary, the putamen and caudate regions start to
atrophy at a much earlier age and have a greater
percentage change between the early stage and end‐stage
of HD compared with hippocampus and thalamus, while
the latter biomarkers have rates of change more similar.
The effect of CAG repeats and initial diagnosis is larger
for the putamen and caudate regions.
5 | DISCUSSION
In this work, we propose a biologically‐inspired latent
variables model to integrate biomarkers that reflect
pathological changes of neurodegenerative disorders to
predict disease progression. A binomial distribution is
used to reflect the aggregated latent neuronal
responses and capture the sigmoidal shape of biomarker
deterioration. Directly linking the biological neural mass
model to statistical model can be considered when
measurements of brain neuronal responses (eg, through
electroencephalogram, EEG or electrocorticography,
ECoG) are available. In this case, the latent Bernoulli
variables can be measured through observed neuronal
responses.
Without direct measures of neural responses, our
model formulates the observed biomarker value as a
manifestation of mean activity of latent states of neural
ensembles. The latent states coincide with the concept
of CR. The resulting marginal model of the observed
biomarkers takes a nonlinear form that is consistent
with the existing literature. The latent inflection point
of each biomarker is linked to a common liability
score modeled by covariates associated with a patient’s
genetic features and baseline measures. The model
integrates biomarkers measured on heterogeneous
scales by mapping them onto a common scale to allow
comparisons across biomarkers and subjects. Corre-
sponding to the “linearization” of a model for nonlinear
data, an EM algorithm is proposed to solve a difficult
optimization with several explicit solutions in the M
step and a one‐dimensional numeric integration in the
E step.
Extension of our method to handle discrete outcomes
can be achieved by assuming a cumulative logistic
distribution with random inflection points. Another
extension is to jointly model time‐to‐disease‐diagnosis,
biomarkers, and clinical signs. When the number of
biomarkers is high, some regularization needs to be
placed on bk and χk, and performing variable selection is
desirable for choosing biomarkers informative of the
latent liability scoreWi . A marker‐specific random effects
can further be included in model (4) to account for
additional correlation between biomarkers. It is also of
interest to extend our model to accommodate multilevel
liability scores (ie, allowing the distribution of a multi-
variate Wi to depend on k), which can further leverage
correlation across domains (eg, cognitive markers and
motor signs), and allow the liability score to be time‐
dependent. However, using multilevel liability scores is
less computationally efficient and may require approx-
imation of the multidimensional integration when the
dimension of biomarkers high. Lastly, here we focus on
PREDICT‐HD study alone, while it is of interest to
include other natural history studies of HD (Biglan et al.,
2016) as well as other disorders (eg, AD, PD, etc) to
integrate data and estimate inflection points more
precisely.
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TABLE 3 Mean squared error (MSE) of testing on 10% out‐of‐
sample data based on 100 sampling data
Evaluation LME GAM Our model
Mean of outsample MSE 3.512 3.451 3.202
SD of outsample MSE 0.331 0.349 0.311
Note: The estimated MSE is based on 10% testing data by fitting linear mixed
effect model (LME), generalized additive model (GAM), and our model on
90% training data. The procedure was repeated 100 times with randomly
sampled data. LME uses the same three covariates as our model. GAM was
fitted using cubic spline basis of age and the three covariates.
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SUPPORTING INFORMATION
Appendices include technical details of the proof of
identifiability (Section A), EM algorithm (Section B),
prediction of future trajectory (Section C) referenced in
Sections 4. They are available with this paper at the
Biometrics website on Wiley Online Library.
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